Delcath is a medical company that makes the HEPZATO KIT and CHEMOSAT for treating cancers in the liver. DCTH reports earnings on Mon, Nov 9, 2026.
Prices, price targets and earnings estimates for DCTH are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in DCTH in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DCTH is in one of them and how their past DCTH trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Delcath Systems
Delcath is a medical company focused on treating cancers that have spread to the liver or started there. Its lead product is the HEPZATO KIT, a combined drug and device treatment approved in the United States for adults with uveal melanoma that has spread to the liver. In Europe, Delcath sells CHEMOSAT, a device used at medical centers to deliver treatment to the liver. Its treatments are performed by interventional radiologists, and the company is based in Queensbury, New York.
